Full Year
ANGO — FY2026 Annual Financial Report Analysis
AngioDynamics grew FY2026 sales 9.5% to $320.2M on 18.4% Med Tech growth, but higher sales, R&D and pay costs absorbed the extra gross profit and the GAAP net loss widened to $36.7M ($0.88 a share).